Monday, August 14, 2017 9:07:23 PM
"Basic and diluted loss per share attributable to common shareholders" = 0.00
Someone please correct me if I'm wrong, but I'm ALMOST CERTAIN that Q2 2017 was now the FIRST TIME Immune Therapeutics did NOT record a LOSS PER SHARE over a 3 month period (due to a gain on settlement of debt).
And to do that WITHOUT revenue is a great sign. We are on the right track.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM